๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors โ€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ€” searchable for business development and competitive intelligence.

676 results for โ€œSolidโ€ Clear

  1. Saruparib, Camizestrant, Datopotamab deruxtecan, PACLITAXEL , Saruparib, DS-8201a, Saruparib, Saruparib

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  2. Selinexor

    Karyopharm Therapeutics Inc

    Solid Tumor Malignancy

    phase 2 small molecule terminated

    1 trial

  3. Sigvotatug vedotin, PF-08634404

    Pfizer Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  4. Surzebiclimab

    BeiGene

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  5. Surzebiclimab

    BEONE MEDICINES AUS PTY LTD

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  6. TAK-188

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  7. TAK-505

    Takeda

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  8. TAK-981

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule completed

    1 trial

  9. TAZEMETOSTAT, IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Adult participants with metastatic or unresectable locally advanced solid tumors.

    phase 2 small molecule active

    1 trial

  10. TNG462

    Tango Therapeutics

    Locally Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  11. TNG462, S095035 tablet 25mg, S095035 tablet 50mg, TNG462, TNG462

    The George Institute

    MTAP-deleted advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  12. TNG908

    Tango Therapeutics

    Locally Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  13. TNG908, TNG908, TNG908, TNG908, MIDAZOLAM

    Tango Therapeutics

    "Ph1: โ€ขLocally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors โ€ขMTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"

    phase 2 small molecule active

    1 trial

  14. TNO155, JDQ443, TNO155, VDT482/ BGB-A317, JDQ443, TNO155, TNO155

    Novartis Pharmaceuticals

    Advance solid tumors harboring the KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  15. TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, LEE011, TEMOZOLOMIDE, TEMOZOLOMIDE

    Novartis Pharmaceuticals

    Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)

    phase 2 small molecule active

    1 trial

  16. TTX-MC138

    Transcode Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  17. Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    The George Institute

    Adult participants with metastatic (advanced) solid tumors.

    phase 2 small molecule active

    1 trial

  18. Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  19. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene

    phase 2 small molecule active

    1 trial

  20. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor

    phase 2 small molecule active

    1 trial

  21. Tislelizumab (BGB-A317)

    BEONE MEDICINES AUS PTY LTD

    MSI-H/dMMR Solid Tumors

    phase 2 small molecule active

    1 trial

  22. Tolinapant, Tolinapant

    Taiho Pharma Netherlands B.V.

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

  23. Tovorafenib, Tovorafenib

    Lacuna Pharma Pty Ltd

    RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patients

    phase 2 small molecule active

    1 trial

  24. TransCon TLR7/8 Agonist, TransCon IL-2 รŸ/าฏ, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ€“3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources